Literature DB >> 11782989

Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms.

Christopher M Gomez1, Ricardo A Maselli, Bhupinder P S Vohra, Manuel Navedo, Joel R Stiles, Pierre Charnet, Kelly Schott, Legier Rojas, John Keesey, Anthony Verity, Robert W Wollmann, Jose Lasalde-Dominicci.   

Abstract

We investigated the basis for a novel form of the slow-channel congenital myasthenic syndrome presenting in infancy in a single individual as progressive weakness and impaired neuromuscular transmission without overt degeneration of the motor endplate. Prolonged low-amplitude synaptic currents in biopsied anconeus muscle at 9 years of age suggested a kinetic disorder of the muscle acetylcholine receptor. Ultrastructural studies at 16 months, at 9 years, and at 15 years of age showed none of the typical degenerative changes of the endplate associated with the slow-channel congenital myasthenic syndrome, and acetylcholine receptor numbers were not significantly reduced. We identified a novel C-to-T substitution in exon 8 of the delta-subunit that results in a serine to phenylalanine mutation in the region encoding the second transmembrane domain that lines the ion channel. Using Xenopus oocyte in vitro expression studies we confirmed that the deltaS268F mutation, as with other slow-channel congenital myasthenic syndrome mutations, causes delayed closure of acetylcholine receptor ion channels. In addition, unlike other mutations in slow-channel congenital myasthenic syndrome, this mutation also causes delayed opening of the channel, a finding that readily explains the marked congenital weakness in the absence of endplate degeneration. Finally, we used serial morphometric analysis of electron micrographs to explore the basis for the progressive weakness and decline of amplitude of endplate currents over a period of 14 years. We demonstrated a progressive widening and accumulation of debris in the synaptic cleft, resulting in loss of efficacy of released neurotransmitter and reduced safety factor. These studies demonstrate the role of previously unrecognized mechanisms of impairment of synaptic transmission caused by a novel mutation and show the importance of serial in vitro studies to elucidate novel disease mechanisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11782989      PMCID: PMC4841278          DOI: 10.1002/ana.10077

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  26 in total

1.  Content of acetylcholine receptor and antibodies bound to receptor in myasthenia gravis, experimental autoimmune myasthenia gravis, and Eaton-Lambert syndrome.

Authors:  J M Lindstrom; E H Lambert
Journal:  Neurology       Date:  1978-02       Impact factor: 9.910

2.  Anconeus muscle: a human muscle preparation suitable for in-vitro microelectrode studies.

Authors:  R A Maselli; D P Mass; B J Distad; D P Richman
Journal:  Muscle Nerve       Date:  1991-12       Impact factor: 3.217

3.  Staining for nerve fiber and cholinesterase activity in fresh frozen sections.

Authors:  T Namba; T Nakamura; D Grob
Journal:  Am J Clin Pathol       Date:  1967-01       Impact factor: 2.493

4.  A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel.

Authors:  A G Engel; E H Lambert; D M Mulder; C F Torres; K Sahashi; T E Bertorini; J N Whitaker
Journal:  Ann Neurol       Date:  1982-06       Impact factor: 10.422

5.  Effects of a monoclonal anti-acetylcholine receptor antibody on the avian end-plate.

Authors:  R A Maselli; D J Nelson; D P Richman
Journal:  J Physiol       Date:  1989-04       Impact factor: 5.182

6.  Mutations in different functional domains of the human muscle acetylcholine receptor alpha subunit in patients with the slow-channel congenital myasthenic syndrome.

Authors:  R Croxen; C Newland; D Beeson; H Oosterhuis; G Chauplannaz; A Vincent; J Newsom-Davis
Journal:  Hum Mol Genet       Date:  1997-05       Impact factor: 6.150

7.  Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit.

Authors:  K Ohno; H L Wang; M Milone; N Bren; J M Brengman; S Nakano; P Quiram; J N Pruitt; S M Sine; A G Engel
Journal:  Neuron       Date:  1996-07       Impact factor: 17.173

8.  Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity.

Authors:  S M Sine; K Ohno; C Bouzat; A Auerbach; M Milone; J N Pruitt; A G Engel
Journal:  Neuron       Date:  1995-07       Impact factor: 17.173

9.  Single acetylcholine-activated channels show burst-kinetics in presence of desensitizing concentrations of agonist.

Authors:  B Sakmann; J Patlak; E Neher
Journal:  Nature       Date:  1980-07-03       Impact factor: 49.962

10.  Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit.

Authors:  K Ohno; D O Hutchinson; M Milone; J M Brengman; C Bouzat; S M Sine; A G Engel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

View more
  17 in total

1.  Phenotypic heterogeneity in a large Thai slow-channel congenital myasthenic syndrome kinship.

Authors:  Rawiphan Witoonpanich; Teeratorn Pulkes; Charungthai Dejthevaporn; Praphan Yodnopklao; Pirada Witoonpanich; Suppachok Wetchaphanphesat; Joan M Brengman; Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-03       Impact factor: 4.296

2.  Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.

Authors:  Haipeng Zhu; Gary E Grajales-Reyes; Vivianette Alicea-Vázquez; Jose G Grajales-Reyes; KaReisha Robinson; Peter Pytel; Carlos A Báez-Pagán; Jose A Lasalde-Dominicci; Christopher M Gomez
Journal:  Exp Neurol       Date:  2014-10-23       Impact factor: 5.330

3.  Limb girdle myasthenia with digenic RAPSN and a novel disease gene AK9 mutations.

Authors:  Ching-Wan Lam; Ka-Sing Wong; Ho-Wan Leung; Chun-Yiu Law
Journal:  Eur J Hum Genet       Date:  2016-12-14       Impact factor: 4.246

4.  Skeletal muscle calpain acts through nitric oxide and neural miRNAs to regulate acetylcholine release in motor nerve terminals.

Authors:  Haipeng Zhu; Bula Bhattacharyya; Hong Lin; Christopher M Gomez
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

Review 5.  What have we learned from the congenital myasthenic syndromes.

Authors:  Andrew G Engel; Xin-Ming Shen; Duygu Selcen; Steven M Sine
Journal:  J Mol Neurosci       Date:  2009-08-18       Impact factor: 3.444

6.  Acetylcholine receptor pathway mutations explain various fetal akinesia deformation sequence disorders.

Authors:  Anne Michalk; Sigmar Stricker; Jutta Becker; Rosemarie Rupps; Tapio Pantzar; Jan Miertus; Giovanni Botta; Valeria G Naretto; Catrin Janetzki; Nausheen Yaqoob; Claus-Eric Ott; Dominik Seelow; Dagmar Wieczorek; Britta Fiebig; Brunhilde Wirth; Markus Hoopmann; Marisa Walther; Friederike Körber; Markus Blankenburg; Stefan Mundlos; Raoul Heller; Katrin Hoffmann
Journal:  Am J Hum Genet       Date:  2008-02       Impact factor: 11.025

7.  A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome.

Authors:  Amina Chaouch; Juliane S Müller; Velina Guergueltcheva; Marina Dusl; Ulrike Schara; Vidosava Rakocević-Stojanović; Christopher Lindberg; Rosana H Scola; Lineu C Werneck; Jaume Colomer; Andres Nascimento; Juan J Vilchez; Nuria Muelas; Zohar Argov; Angela Abicht; Hanns Lochmüller
Journal:  J Neurol       Date:  2011-08-07       Impact factor: 4.849

Review 8.  Decoding pathogenesis of slow-channel congenital myasthenic syndromes using recombinant expression and mice models.

Authors:  José David Otero-Cruz; Carlos Alberto Báez-Pagán; Luisamari Dorna-Pérez; Gary Emanuel Grajales-Reyes; Rosaura Teresa Ramírez-Ordoñez; Carlos A Luciano; Christopher Manuel Gómez; José Antonio Lasalde-Dominicci
Journal:  P R Health Sci J       Date:  2010-03       Impact factor: 0.705

9.  Novel beta subunit mutation causes a slow-channel syndrome by enhancing activation and decreasing the rate of agonist dissociation.

Authors:  Manuel F Navedo; José A Lasalde-Dominicci; Carlos A Báez-Pagán; Luzed Díaz-Pérez; Legier V Rojas; Ricardo A Maselli; Julie Staub; Kelly Schott; Roberto Zayas; Christopher M Gomez
Journal:  Mol Cell Neurosci       Date:  2006-04-19       Impact factor: 4.314

10.  Determinants of the repetitive-CMAP occurrence and therapy efficacy in slow-channel myasthenia.

Authors:  Li Di; Hai Chen; Yan Lu; Duygu Selcen; Andrew G Engel; Yuwei Da; Xin-Ming Shen
Journal:  Neurology       Date:  2020-09-09       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.